Company: CDT
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001493152-25-022373
Chunk: 68

Company: CDT Equity Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 2
Chunk 68
---
 drug
development cycle and giving CDT Equity a competitive advantage in the sector.

Through
this relationship, CDT Equity will gain access to cutting-edge predictive models and dashboards, enabling the Company to evaluate
drug candidates, streamline clinical trials, and optimize asset management with real-time data. These tools will drive faster, more
accurate decisions, improving efficiency and reducing costs. By leveraging these insights, CDT Equity can differentiate itself in a
competitive sector and gain unique data-driven insights that position the Company for success across both its current and future
asset portfolio.

A
further partnership with Manoira enables CDT Equity to expand the scope of its drug portfolio into the animal health market in a cost-efficient
manner. This collaboration allows us to accelerate the understanding of the mechanism of action, safety, and potential efficacy of its
portfolio across multiple species, while retaining 100% ownership of all data and intellectual property generated relating to human
applications. This is expected to enhance the core human therapeutic pipeline but also opens potential new revenue streams in the high-growth
veterinary market.

Repositioning
CDT Equity enables the Company to explore multiple opportunities in the healthcare, biotech and broader technology innovation. The Board
continues to evaluate a cryptocurrency treasury reserve strategy, collaborating with consultants to best advise a novel market which has
seen significant recent activity and success for respective stakeholders. Long-term exposure to digital assets can present both strategic
and financial benefits as part of a diversified capital management approach.

Operating
with a lean disease-agnostic model, CDT Equity prioritizes speed, adaptability, and capital efficiency. We avoid the cost burden of
late-stage clinical trials, focusing instead on high-leverage development strategies. Led by highly experienced executives: Dr.
Freda Lewis-Hall, former Chief Medical Officer of Pfizer Inc., the Chair of the Company’s Board; Dr. Andrew Regan, CEO and
James Bligh, CFO. Our management team includes active senior scientists who have an extensive understanding of the pharmaceuticals
market, supporting our strategy of developing clinical assets in a cost-efficient manner focused on therapeutic efficacy.

In
2024, AstraZeneca granted a license to the Company under certain intellectual property rights controlled by AstraZeneca related to HK-4
Glucokinase activators AZD1656 and AZD5658 in all indications and myeloperoxidase inhibitor AZD5904 for the treatment, prevention, and
prophylaxis of idiopathic male infertility. The